RecruitingN/Aketamine

IV Ketamine Vs. in Esketamine for MDD TRD

NCT ID

NCT06488586

Target Enrollment

80 participants

Start Date

2023-03-20

Est. Completion

2026-10-20

About This Study

The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suicidal ideations. Participants are already taking antidepressants and/or antipsychotics as part of their regular medical care for depression,

Conditions Studied

Treatment Resistant Depression

Interventions

•Low dose IV Ketamine vs. IN Esketamine

Eligibility

Age:18 Years - 75 Years

Healthy Volunteers:No

View full eligibility criteria

Inclusion Criteria:

* Adult outpatients (18-75 years old) with unipolar depression experiencing major depressive episodes as determined by the DSM5 and characterized as MDD-TRD (diagnosed with major depressive disorder as outlined by the DSM5) and experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode

Exclusion Criteria:

* Individuals with psychosis, main diagnosis of personality disorder, uncontrolled hypertension, substance abuse, currently pregnant or breastfeeding, or who had a previous negative reaction to ketamine or esketamine, were ineligible to receive IV ketamine or IN esketamine.

Study Locations (1)

Providence Care Hospital

Kingston, Ontario, Canada